<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884139</url>
  </required_header>
  <id_info>
    <org_study_id>GESIDA11720</org_study_id>
    <nct_id>NCT04884139</nct_id>
  </id_info>
  <brief_title>DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV:</brief_title>
  <acronym>PASO-DOBLE</acronym>
  <official_title>DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV: an Open-label Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion SEIMC-GESIDA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion SEIMC-GESIDA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesize that DTG/3TC will be non-inferior to BIC/FTC/TAF with a 4% margin in&#xD;
      virologically suppressed HIV-infected patients. The study will allow claiming for&#xD;
      Superiority. Assuming that both DTG and BIC may lead to similar weight gains (approximately 1&#xD;
      kg after 48 weeks) in virologically suppressed HIV-infected patients and that TAF may induce&#xD;
      a further weight gain (approximately 1 kg after 48 weeks), also hypothesize that switching to&#xD;
      BIC/FTC/TAF may lead to greater weight gain than switching to DTG/3TC over 48 weeks.&#xD;
&#xD;
      This trial is a Phase IV, open-label, randomized multicentre clinical trial evaluating the&#xD;
      efficacy of DTG/3TC versus BIC/FTC/TAF for the maintenance of virological suppression in HIV&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomly assigned in a 1:1 ratio to receive DTG/3TC or BIC/FTC/TAF.&#xD;
      Randomization will be stratified by sex and TAF use at baseline. At least 33% of the patients&#xD;
      included will be women.&#xD;
&#xD;
      The investigatora will also endeavour to recruit as many non-Caucasian participants as&#xD;
      possible.&#xD;
&#xD;
      Patients with TAF-containing regimens at baseline will be limited to 25% or less of the total&#xD;
      number of participants. Three sub-studies will be performed: Omics sub-study ; Senescence&#xD;
      sub-study; Fat biopsies sub-study.&#xD;
&#xD;
      Omics sub-study: Assess the mechanistic pathways involved on weight changes associated with&#xD;
      switching to BIC/FTC/TAF vs. DTG/3TC.&#xD;
&#xD;
      Senescence sub-study: Assess the potential effects on the telomere length, epigenetic age and&#xD;
      oxidative stress markers of switching to BIC/FTC/TAF vs. DTG/3TC.&#xD;
&#xD;
      Fat biopsies sub-study: To assess potential effects of switching to BIC/FTC/TAF vs.&#xD;
&#xD;
      DTG/3TC on expression of marker genes of mitochondrial function, adipogenesis, and&#xD;
      inflammation in subcutaneous fat tissue. Assays on adipose tissue gene expression will be&#xD;
      complemented by analysis in serum of adipokines representative of adipose tissue function&#xD;
      (leptin, adiponectin), and inflammation biomarkers (TNFalpha, MCP-1, IL-6, IL- 8, IL-10,&#xD;
      IL-18).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with plasma HIV-1 RNA ≥50 copies/mL</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with plasma HIV-1 RNA ≥50 copies/mL</measure>
    <time_frame>week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with plasma HIV-1 RNA &lt;50 copies/mL</measure>
    <time_frame>Week 48 and week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute weight</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI change</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with weight change &gt;5%</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values in CD4+ cells count</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CD4+ cells count</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values CD4:CD8 ratio</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes CD4:CD8 ratio</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total and regional (trunk and extremities) fat by DXA</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total and regional (trunk and extremities) fat-free mass by DXA</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lumbar and hip bone mineral density (BMD) by DXA</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change trabecular bone score (TBS) by DXA</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subcutaneous and visceral fat (CT)</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucose cholesterol, triglycerides), and FIB-4 score</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change insulin cholesterol, triglycerides), and FIB-4 score</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HOMA-IR cholesterol, triglycerides), and FIB-4 score</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c cholesterol, triglycerides), and FIB-4 score</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma lipids (total, HDL, and LDL) cholesterol, triglycerides), and FIB-4 score</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in estimated glomerular filtration rate (CKD-EPI)</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in urinary protein/creatinine</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Basal, week 48 y week 96</time_frame>
    <description>Systolic and Diastolic Blood Pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sleep quality (Pittsburg Sleep Quality Index)</measure>
    <time_frame>From basal, until week 96 , in each visit</time_frame>
    <description>Pittsburg Sleep Quality Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety and depression (HAD) quality of life (HIV Symptom Index questionnaire / Symptom Distress Module (HIV-SI/SDM</measure>
    <time_frame>From basal, until week 96 , in each visit</time_frame>
    <description>Anxiety and depression (HAD) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life (HIV Symptom Index questionnaire / Symptom Distress Module (HIV-SI/SDM)</measure>
    <time_frame>From basal, until week 96 , in each visit</time_frame>
    <description>Quality of life (HIV-SI/SDM) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events (clinical and laboratory)</measure>
    <time_frame>From basal, until week 96 , in each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events leading to treatment discontinuation.</measure>
    <time_frame>From basal, until week 96 , in each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of genotypic resistance mutations in participants with virological failure</measure>
    <time_frame>Week 48 and week 96</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Dovato arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DTG/3TC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biktarvy arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BIC/FTC/TAF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir/Lamivudine as a single pill</intervention_name>
    <description>- Dose: Dolutegravir 50mg/ Lamivudine 300 mg -Route of adminstration: oral -Schedule of administration: once a day for 96 weeks.</description>
    <arm_group_label>Dovato arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill.</intervention_name>
    <description>Dose: Bictegravir 50 mg/Emtricitabine 200 mg /Tenofovir alafenamide 25 mg&#xD;
Route of adminstration: oral&#xD;
Schedule of administration: once a day for 96 weeks.</description>
    <arm_group_label>Biktarvy arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Understanding the study information provided and being capable of giving written&#xD;
             informed consent.&#xD;
&#xD;
          2. Confirmed HIV infection.&#xD;
&#xD;
          3. ≥18 years of age on the day of screening.&#xD;
&#xD;
          4. HIV RNA &lt;50 copies/mL for at least 24 weeks before screening.&#xD;
&#xD;
          5. Receiving any regimen for HIV containing more than 1 pill a day or any single tablet&#xD;
             regimen containing at least one of the following: cobicistat-boosting, efavirenz, or&#xD;
             tenofovir disoproxyl fumarate, for at least 24 weeks before screeningPatients with TAF&#xD;
             are expected from cobiscitat-boosting single tablet regimens containing darunavir or&#xD;
             elvitegravir and from more-than-1-pill-a-day regimens containing TAF/FTC; their&#xD;
             participation will be limited to ≤25%. Patients will be stratified according to the&#xD;
             presence or not of TAF in their regimens.&#xD;
&#xD;
          6. No evidence of previous viral failure.&#xD;
&#xD;
          7. No known or suspected resistance to study drugs.&#xD;
&#xD;
          8. Females of childbearing potential, must be using highly effective methods of&#xD;
             contraception from study inclusion and for at least 4 weeks after last study visit;&#xD;
             all female volunteers must be willing to undergo urine pregnancy testing at the time&#xD;
             points specified in the schedules of events.&#xD;
&#xD;
          9. Clinical stability: Participants who are healthy (other than HIV infection) as&#xD;
             determined by the Investigator or medically qualified designee based on a medical&#xD;
             evaluation including medical history, laboratory tests, and cardiac monitoring.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is pregnant or lactating at the screening visit or at any time during the study or is&#xD;
             planning on becoming pregnant over the duration of the study.&#xD;
&#xD;
          2. Evidence of Hepatitis B virus infection based on at least one positive result of&#xD;
             testing at Screening for Hepatitis B surface antigen (HBsAg) and Hepatitis B core&#xD;
             antibody (anti- HBc).&#xD;
&#xD;
          3. Previous or current therapy with dolutegravir or bictegravir.&#xD;
&#xD;
          4. History of allergy to study drugs or their components.&#xD;
&#xD;
          5. Liver disease as defined by ALT &gt;= 5x ULN or ALT &gt;=3xULN and Bili &gt;=1.5xULN (with &gt;35%&#xD;
             direct bilirubin).&#xD;
&#xD;
          6. Unstable liver disease (as defined by the presence of ascites, encephalopathy,&#xD;
             coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice),&#xD;
             cirrhosis, known biliary abnormalities (apart from hyperbilirubinemia or jaundice due&#xD;
             to Gilbert's syndrome or asymptomatic gallstones);&#xD;
&#xD;
          7. Subjects with severe hepatic impairment (Class C) as determined by Child-Pugh&#xD;
             classification and/or anticipated need for Hep C treatment.&#xD;
&#xD;
          8. Kidney disease as defined by CKD-EPI &lt;50ml/min.&#xD;
&#xD;
          9. Any recently (&lt;=6 months) diagnosed clinical condition or recently (&lt;=6 months)&#xD;
             initiated concomitant therapy (see Section 6.5) that may primarily affect weight or&#xD;
             body composition. E.g., including but not limited to endocrine disorders, osteoporosis&#xD;
             or medications to treat these clinical conditions, with the exception of controlled&#xD;
             diabetes mellitus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esteban Martinez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Clinc de Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Yllescas</last_name>
    <phone>0034 915568025</phone>
    <email>myllescas@f-sg.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Herminia Esteban</last_name>
    <phone>0034 915568025</phone>
    <email>hesteban@f-sg.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>H. de Elche</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Mar Massia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. de Torrecárdenas</name>
      <address>
        <city>Almería</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Antonio Collado, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Juan Manuel Tiraboschi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. de Igualada</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jhon Fredy Rojas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Roberto Güerri-Fernandez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. San Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Vicens Diaz de Brito, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Sant Creu y Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Pere Domingo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Vall de Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Adria Curran, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUAC</name>
      <address>
        <city>Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Álvaro Mena, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Juan Ramón Jimenez</name>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Dolores Merino, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Pablo Ryan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jesus Sanz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Príncipe de asturias</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose Sanz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Univ. La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose R Arribas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Univ. Puerta de Hierr</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Sara De la Fuente, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Julián Olalla, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Reina Sofía</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Enrique Bernal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Victor Asensi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Francisco Fanjul, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Son Llatzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Aroa Villoslada, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. de Valme</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Juan Antonio Pineda, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Francisco Vidal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Clínico Univ. de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Mª José Galindo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H Clinico Univ. de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Carlos Dueñas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Alvaro Cunquerio</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Antonio Ocampo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Clinico Univ. Lozano Bleza</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Mº José Crusells, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

